# Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

> **NCT05293665** · PHASE3 · UNKNOWN · sponsor: **Vaxxinity, Inc.** · enrollment: 944 (actual)

## Conditions studied

- COVID-19 Vaccines

## Interventions

- **BIOLOGICAL:** UB-612
- **BIOLOGICAL:** BNT162b2 vaccine
- **BIOLOGICAL:** ChAdOx1-S vaccine
- **BIOLOGICAL:** Sinopharm BIBP

## Key facts

- **NCT ID:** NCT05293665
- **Lead sponsor:** Vaxxinity, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-16
- **Primary completion:** 2022-11
- **Final completion:** 2023-09
- **Target enrollment:** 944 (ACTUAL)
- **Last updated:** 2022-10-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293665, "Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05293665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*